You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 136 No. 1, January 1976 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Propranolol as Primary Therapy for Thyrotoxicosis

Results of a Long-Term Prospective Study

Ernest L. Mazzaferri, MD; James C. Reynolds, MD; Lt Col Robert L. Young, MC; Lt Col Charles N. Thomas, MC; Alfred F. Parisi, MD

Arch Intern Med. 1976;136(1):50-56.


Abstract

It has been suggested that propranolol hydrochloride alone is effective in the treatment of thyrotoxicosis. To test this hypothesis, eight mildly thyrotoxic individuals were prospectively studied for an average of eight months, during which propranolol alone was administered and thyroid function tests, cardiac systolic time intervals, and body densities were sequentially measured. Two patients became euthyroid. The others had adequate but incomplete symptomatic control. Weight loss was not corrected, but no changes in lean body mass were induced. The augmented myocardial contractility of thyrotoxicosis, as determined by systolic time intervals, improved but failed to return completely to normal. Thus, systolic time intervals are a practical means of following the peripheral response to chronic beta-adrenergic blockade in thyrotoxic patients. However, these observations do not support the use of propranolol alone as the first choice of therapy for thyrotoxicosis.

(Arch Intern Med 136:50-56, 1976)



Author Affiliations

USAF; USAF

From the Division of Endocrinology and Metabolism, Ohio State University Hospitals, Columbus (Drs. Mazzaferri and Reynolds); the divisions of endocrinology and metabolism (Dr. Young) and cardiology (Dr. Thomas), Wilford Hall USAF Medical Center, San Antonio, Texas; and the Division of Cardiology, Baltimore Veterans Administration Hospital, Baltimore (Dr. Parisi).


Footnotes

Received for publication Jan 7, 1975; accepted March 26.

Reprint requests to Room N-1111 University Hospital, 410 W Tenth Ave, Columbus, OH 43210 (Dr. Mazzaferri).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Common Factor for Cardiac or Respiratory Failure in SIDS
Jones
CLIN PEDIATR 1995;34:172-172.
 

The Effect of Diltiazem, a Calcium Channel--Blocking Drug, on Cardiac Rate and Rhythm in Hyperthyroid Patients
Roti et al.
Arch Intern Med 1988;148:1919-1921.
ABSTRACT  

Symptom Rating Scale for Assessing Hyperthyroidism
Klein et al.
Arch Intern Med 1988;148:387-390.
ABSTRACT  

Complications of Propranolol Use in Neonatal Thyrotoxicosis
NEWMAN et al.
Arch Pediatr Adolesc Med 1980;134:707-708.
ABSTRACT  

Cardiac Systolic Time Intervals in Thyroid Disorders
Mazzaferri and Lewis
Arch Intern Med 1978;138:1470-1471.
ABSTRACT  

Effects of Guanadrel on Patients With Thyrotoxicosis
Rubenfeld et al.
Arch Intern Med 1978;138:1106-1108.
ABSTRACT  

Propranolol as Treatment for Thyrotoxicosis
Biran
Arch Intern Med 1976;136:1197-1198.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1976 American Medical Association. All Rights Reserved.